Meningeal metastasis is a kind of serious complications of malignant tumor cells invading the leptomeninges and spreading along the cerebrospinal fluid, whose detection rate is gradually increased with advanced imaging diagnostic techniques. Although traditional intrathecal chemotherapy can prolong the survival of patients with meningeal metastasis, its efficacy is still unsatisfactory. In recent years, new intrathecal injection regimens, targeted drug therapy, and proton radiotherapy have significantly improved the prognosis of some patients with meningeal metastasis; however, these treatment regimens still require high-quality evidence-based medical evidences. This article reviews the recent advance in intrathecal injection, systemic treatments (systemic chemotherapy, molecular targeted therapy and immunotherapy), and radiotherapy of meningeal metastasis in recent years, so as to help selecting treatment regimens for meningeal metastasis in clinical practice.

Meningeal metastasis is a kind of serious complications of malignant tumor cells invading the leptomeninges and spreading along the cerebrospinal fluid, whose detection rate is gradually increased with advanced imaging diagnostic techniques. Although traditional intrathecal chemotherapy can prolong the survival of patients with meningeal metastasis, its efficacy is still unsatisfactory. In recent years, new intrathecal injection regimens, targeted drug therapy, and proton radiotherapy have significantly improved the prognosis of some patients with meningeal metastasis; however, these treatment regimens still require high-quality evidence-based medical evidences. This article reviews the recent advance in intrathecal injection, systemic treatments (systemic chemotherapy, molecular targeted therapy and immunotherapy), and radiotherapy of meningeal metastasis in recent years, so as to help selecting treatment regimens for meningeal metastasis in clinical practice.

Objective:To analyze the normal expression levels of different lung cancer tumor markers(TM)in the cerebrospinal fluid and to explore the influence of serum TM levels and brain parenchymal metastasis,to more accurately determine whether the cerebrospinal fluid TM levels of patients with suspected meningeal metastasis is elevated.Methods:The clinical data of 80 patients diagnosed with non-lepto-meningeal metastasis at Tianjin Medical University Cancer Hospital between January 2015 and February 2024 were collected,including 16 patients without lung cancer and 64 patients with lung cancer.Normal TM levels in the cerebrospinal fluid of patients without lung cancer and the difference in TM levels between the cerebrospinal fluid and serum samples were analyzed.The correlation between serum and cerebrospinal fluid TM levels was also analyzed.We then compared the differences in TM levels in the cerebrospinal fluid between groups with brain parenchymal metastasis and without brain parenchymal metastasis.Results:Normal levels of TPSA,CA19-9,CEA,Cyfra21-1,and SCC in the cerebrospinal fluid were lower than those in the serum(P<0.05);however,the levels of ProGRP and NSE in the cerebrospinal fluid were higher than those in the serum(P<0.05).The levels of TPSA,SCC,ProGRP,NSE,CEA,CA19-9,and Cyfra21-1 in the cerebrospinal fluid did not correlate with those in the serum(all P>0.05).The cerebrospinal fluid levels of TPSA,SCC,ProGRP,and CA19-9 were not significantly increased in patients with brain parenchymal metastasis compared to those in patients without brain parenchymal metastasis(P>0.05).Al-though CEA and Cyfra21-1 levels increased(P<0.05),their median values increased by less than 2 times and were all within the reference range;whereas,the level of NSE in the group with brain parenchymal metastasis was lower than that in the control group.Conclusions:The basal levels of ProGRP and NSE in normal cerebrospinal fluid were significantly higher than those in the serum;whereas,the expression levels of other TM in the cerebrospinal fluid were significantly lower than those in the serum.Whether the levels of TM in the serum were elevated and whether brain parenchymal metastasis was present,did not have a clinically significant impact on the TM levels in the cerebrospinal fluid.

Meningioma is the most common type of primary intracranial tumor and includes grade I,II and III by the world health organization(WHO)classification in 2021.With the increase of grade,the higher the recurrence rate of tumor,the worse the prognosis.Surgery is the main treatment,and radiotherapy is used for residual or recurrent tumors.However,some patients often lost the opportunity of surgery and radiotherapy who recurred after multiple surgeries or radiotherapy.Medical treatment is limited.Therefore,effective treatment is an urgent problem to be solved.In recent years,immunotherapy has achieved good efficacy in a variety of malignant tumors.Meningioma also harbors abundant immune microenvironment basing on the large of evidence of genome and infiltrated immune cells of meningioma,immunotherapy may be a choice for the treatment of recurrent or refractory meningioma.This article mainly reviews the components of the immune microenvironment in meningioma and the progress of immunotherapy,and summarizes the expression and application of immune checkpoint proteins in the meningioma in the past years,aiming to find out effective immune targets for clinical transformation and bring new hope for meningioma patients.

Meningioma is the most common type of primary intracranial tumor and includes grade I,II and III by the world health organization(WHO)classification in 2021.With the increase of grade,the higher the recurrence rate of tumor,the worse the prognosis.Surgery is the main treatment,and radiotherapy is used for residual or recurrent tumors.However,some patients often lost the opportunity of surgery and radiotherapy who recurred after multiple surgeries or radiotherapy.Medical treatment is limited.Therefore,effective treatment is an urgent problem to be solved.In recent years,immunotherapy has achieved good efficacy in a variety of malignant tumors.Meningioma also harbors abundant immune microenvironment basing on the large of evidence of genome and infiltrated immune cells of meningioma,immunotherapy may be a choice for the treatment of recurrent or refractory meningioma.This article mainly reviews the components of the immune microenvironment in meningioma and the progress of immunotherapy,and summarizes the expression and application of immune checkpoint proteins in the meningioma in the past years,aiming to find out effective immune targets for clinical transformation and bring new hope for meningioma patients.

Circular RNAs(circRNAs)are involved in various biological processes and disease pathogenesis.However,only a small number of functional circRNAs have been identified among hundreds of thousands of circRNA species,partly because most current methods are based on cir-cular junction counts and overlook the fact that a circRNA is formed from the host gene by back-splicing(BS).To distinguish the expression difference originating from BS or the host gene,we pre-sent differentially expressed back-splicing(DEBKS),a software program to streamline the discov-ery of differential BS events between two rRNA-depleted RNA sequencing(RNA-seq)sample groups.By applying to real and simulated data and employing RT-qPCR for validation,we demon-strate that DEBKS is efficient and accurate in detecting circRNAs with differential BS events between paired and unpaired sample groups.

OBJECTIVETo explore clinical characteristics， treatment and prognosis of primary central nervous system lymphoma(PCNSL).

METHODSRetrospective analysis, Kaplan-Meier analysis and Log-rank test were conducted on 30 PCNSL patients from 2006 to 2014 in our hospital.

RESULTSThe median age of this cohort (14 males and 16 females) was 57.4 years old. 18 cases had single tumor, 12 cases multiple. 17 cases presentd with intracranial hypertension and 13 cases focal neurological deficits. 13 cases (62%) were diffuse large B cell lymphoma. About 60% patients received combination therapy including surgery, radiotherapy or chemotherapy. 63.3% complete remission rate (CR) was achieved for all patients. Kaplan-Meier analysis and Log-rank test showed the median overall survival (OS) was 24 months, the rates of 2-year survival, 5-year survival, 6-month progression-free survival(PFS) and 1-year free-progressed survival (PFS) were as of 46.7%, 13.3%, 60.0% and 43.3% respectively. The median OS of 11 patients received whole brain radiotherapy(WBRT)combined with chemotherapy was 48 months. The median OS of 7 patients treated with stereotactic radiosurgery(SRS) combined with chemotherapy had no significant difference when compared to the former (P=0.233). Survive analysis showed that age was prognostic factor for PCNSL patients(P=0.030).

CONCLUSIONDiffuse large B cell lymphoma was the main type of PCNSL, single or multiple location, presented with increased intracranial hypertension or focal neurological deficits. Age was the key prognostic factor for patients. Surgery was suitable for patients with supertentorial and superficial tumor or with acute intracranial hypertension syndrome. SRS was a feasible local therapy which alleviated the symptoms and led to less toxicity. PCNSL patients might benefit from multimode therapy.

Central Nervous System Neoplasms ; Combined Modality Therapy ; Disease-Free Survival ; Female ; Humans ; Kaplan-Meier Estimate ; Lymphoma ; Male ; Middle Aged ; Prognosis ; Remission Induction ; Retrospective Studies

Olfactory neuroblastoma is a rare malignant tumor. Although multiple therapeutic modalities including surgery, radio-therapy, or chemotherapy could be used in patients with olfactory neuroblastoma, no standardized treatment has been achieved. This re-view introduces a case of adult olfactory neuroblastoma treated by a multiple disciplinary team in Tianjin Medical University Cancer In-stitute and Hospital. This review also aims to explore a complete set of diagnostic and treatment practices for the benefit of future pa-tients.

OBJECTIVETo study the efficacy of biological organic zinc in the treatment of chronic bacterial prostatitis (CBP).

METHODSSixty-one CBP patients were randomized into two groups: Group A (39 cases) was supplemented with organic zinc after routine antibiotic treatment, Group B (22 cases) was given routine antibiotic treatment only. NIH-CPIS (including pain, urinary symptoms, quality of life) and urodynamic indexes were used to evaluate the efficacy of biological organic zinc in the treatment of CBP.

RESULTSThe NIH-CPIS (including pain, urinary symptoms, quality of life) and the maximum urethra closure pressure (MUCP) were markedly decreased after the zinc treatment, compared with the non-zinc group(P < 0.05).

CONCLUSIONIt is suggested that biological organic zinc is effective for the treatment of CBP.

Adult ; Aged ; Bacterial Infections ; drug therapy ; Chronic Disease ; Humans ; Male ; Middle Aged ; Prostatitis ; drug therapy ; physiopathology ; Urodynamics ; Zinc ; therapeutic use

Fibroblasts, reticular cells and macrophages are the important components of bone marrow hemopoietic in liquid to study whether HP-Ⅱ-E(Hydroxyproli- ne-2-epimerase, EC5, 1, 1,a) is involved in the synthesis of functional proteins of stromal cells. The femoral bone of 6 to 8 week-old 615 mice were made in suspension for cell culture in vitro. DMEM medium supplied with 25% calf serum was used After one to fifteen day's attaching incubation in stationary liquid the culture cells were stained with Giemsa, nonspecific esterase and HP-Ⅱ-E at different intervals. From the third day of the incubation, reticular cells began to develop form- ing stallate cells of the bone marrow. During an earlier time, enzymatic reaction was only observed in the nuclear membrance, but after three day's culture all the enzymatic activity in the cells increased dramatically. The enzymatic reac- tive granules were abundant in the outer cytoplasma of the stallate cells and fibroblasts and the cytoplasma of the macrophages. It was observed that hyd- roxyproline was changed by epimerase,